- Home
- IBRX vs CLDX Comparison
IBRX vs CLDX Comparison
Compare IBRX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CLDX
- Stock Information
- Founded
- IBRX 2014
- CLDX 1983
- Country
- IBRX United States
- CLDX United States
- Employees
- IBRX N/A
- CLDX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IBRX Health Care
- CLDX Health Care
- Exchange
- IBRX Nasdaq
- CLDX Nasdaq
- Market Cap
- IBRX 1.9B
- CLDX 1.7B
- IPO Year
- IBRX N/A
- CLDX 2008
- Fundamental
- Price
- IBRX $3.42
- CLDX $22.46
- Analyst Decision
- IBRX Strong Buy
- CLDX Buy
- Analyst Count
- IBRX 3
- CLDX 8
- Target Price
- IBRX $13.58
- CLDX $61.86
- AVG Volume (30 Days)
- IBRX 6.0M
- CLDX 774.1K
- Earning Date
- IBRX 03-18-2025
- CLDX 03-04-2025
- Dividend Yield
- IBRX N/A
- CLDX N/A
- EPS Growth
- IBRX N/A
- CLDX N/A
- EPS
- IBRX N/A
- CLDX N/A
- Revenue
- IBRX $7,332,000.00
- CLDX $9,976,000.00
- Revenue This Year
- IBRX $2,359.81
- CLDX N/A
- Revenue Next Year
- IBRX $808.10
- CLDX N/A
- P/E Ratio
- IBRX N/A
- CLDX N/A
- Revenue Growth
- IBRX 1218.71
- CLDX 128.55
- 52 Week Low
- IBRX $2.28
- CLDX $20.91
- 52 Week High
- IBRX $10.53
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- CLDX 42.55
- Support Level
- IBRX $3.35
- CLDX $22.38
- Resistance Level
- IBRX $4.27
- CLDX $23.69
- Average True Range (ATR)
- IBRX 0.31
- CLDX 1.07
- MACD
- IBRX 0.04
- CLDX 0.03
- Stochastic Oscillator
- IBRX 29.17
- CLDX 44.67
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.